Cargando…

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633864/ https://www.ncbi.nlm.nih.gov/pubmed/36349202 http://dx.doi.org/10.1002/cti2.1429

Ejemplares similares

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
por: Alvarez‐Fernández, Carmen, et al.
Publicado: (2021)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
por: Guo, Jing, et al.
Publicado: (2022)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
por: Wen, Hairuo, et al.
Publicado: (2022)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015)

Clinical chimeric antigen receptor T‐cell therapy: a new and promising treatment modality for glioblastoma
por: Brown, Michael P, et al.
Publicado: (2021)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
por: Abbott, Rebecca C, et al.
Publicado: (2021)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
por: Yin, Zixun, et al.
Publicado: (2021)

The Comparison Between Microwave and Autoclave as Antigen Retrieval Methods for Immunohistochemical Detection of CD15 and CD30 in Hodgkin’s Lymphoma
por: Kosari, Farid, et al.
Publicado: (2018)

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum]
Publicado: (2020)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
por: Yegya-Raman, Nikhil, et al.
Publicado: (2023)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study [Corrigendum]
Publicado: (2016)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas
por: Wang, Rong, et al.
Publicado: (2018)

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
por: Zhang, Wen-ying, et al.
Publicado: (2016)

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma
por: Ahrendsen, Jared T., et al.
Publicado: (2021)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

2718. Prevalence of Infections Following Anti-CD30 Targeted Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory Lymphoma
por: Mohnasky, Michael C, et al.
Publicado: (2023)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
por: Hansen, Hinrich P., et al.
Publicado: (2020)

Corrigendum to “Improvement of Memory by Means of Ultra-Low Doses of Antibodies to S-100B Antigen”
por: Evidence-Based Complementary and Alternative Medicine,
Publicado: (2020)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
por: Kanwal, Bushra
Publicado: (2021)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Ex vivo induction of antitumor DEC-205(+) CD11c(+) cells in a murine neuroblastoma model by co-stimulation with doxorubicin, lipopolysaccharide and interleukin-4
por: Inoue, Seiichiro, et al.
Publicado: (2020)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
por: Zhou, Xuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_epkih10tp6ugfrmuggiit6v9dc